REG - Oncimmune Hldngs PLC - Holdings in Company

Oncimmune HoldingsAnnouncement

08/06/2020 07:00

RNS Number : 1879P
  
Oncimmune Holdings PLC
  
08 June 2020
  
 

Oncimmune Holdings plc
 
("Oncimmune" or the "Company")
 
Holdings in Company
 
Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, announces that on 5 June 2020 it received a Notification of Major Holdings in shares as set out below. 
 
To enable him to focus on other activities, Mr Sharp stepped down as a non-executive Director of the Company on 4 May 2020. 
 
On 4 June 2020, Mr Sharp transferred his entire holding of 4,280,749 ordinary shares of 1p in the Company ("Shares") into a blind trust ("Trust") of which he remains the sole beneficiary (as set out in the first TR-1 below) but over which he has no control. 
 
In addition, on the same day, the Trust acquired, at the direction of the trustee, a further 166,251 Shares, increasing  its holding in the Company to 4,447,000 Shares equal to 7% of the total issued share capital (as set out in the second  TR-1 below).
 
 
TR-1: Standard form for notification of major holdings
 



NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)










1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: 


Oncimmune Holdings PLC




1b. Please indicate if the issuer is a non-UK issuer  (please mark with an "X" if appropriate)




Non-UK issuer








2. Reason for the notification (please mark the appropriate box or boxes with an "X")




An acquisition or disposal of voting rights


X




An acquisition or disposal of financial instruments








An event changing the breakdown of voting rights








Other (please specify): Transfer of Shares








3. Details of person subject to the notification obligation




Name


Richard Sharp




City and country of registered office (if applicable)








4. Full name of shareholder(s) (if different from 3.)




Name


Blind Trust (Richard Sharp)




City and country of registered office (if applicable)








5. Date on which the threshold was crossed or reachedvi:


04/06/2020




6. Date on which issuer notified (DD/MM/YYYY):


05/06/2020




7. Total positions of person(s) subject to the notification obligation








% of voting rights attached to shares (total of 8. A)


% of voting rights through financial instruments

(total of 8.B 1 + 8.B 2)


Total of both in % (8.A + 8.B)


Total number of voting rights of issuer




Resulting situation on the date on which threshold was crossed or reached


6.7%






6.7%


63,500,047




Position of previous notification (if 
applicable)




























 



8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii




A: Voting rights attached to shares




Class/type of

shares
ISIN code (if possible)


Number of voting rights


% of voting rights




Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)


Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)


Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)


Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)




GB00BYQ94H38


4,280,749






6.7%




















































SUBTOTAL 8. A


4,280,749


6.7%




 
 




B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))




Type of financial instrument


Expiration

date


Exercise/

Conversion Period


Number of voting rights that may be acquired if the instrument is 
exercised/converted.


% of voting rights














































































SUBTOTAL 8. B 1












 
 




B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))




Type of financial instrument


Expiration

date


Exercise/

Conversion Period 


Physical or cash 
settlement


Number of voting rights 


% of voting rights






























































































SUBTOTAL 8.B.2












 
 
 















 



9. Information in relation to the person subject to the notification obligation (please mark the 
applicable box with an "X")




Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer


X




Full chain of controlled undertakings through which the voting rights and/or the

financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary)








Name


% of voting rights if it equals or is higher than the notifiable threshold


% of voting rights through financial instruments if it equals or is higher than the notifiable threshold


Total of both if it equals or is higher than the notifiable threshold




































































































10. In case of proxy voting, please identify:




Name of the proxy holder








The number and % of voting rights held








The date until which the voting rights will be held














11. Additional information




Richard Sharp's shares transferred to a Blind Trust of which he is the sole beneficiary and over which he has no control.










 



Place of completion


London, United Kingdom
 




Date of completion


04-Jun-2020
 



 




 
TR-1: Standard form for notification of major holdings
 



NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)










1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: 


Oncimmune Holdings PLC




1b. Please indicate if the issuer is a non-UK issuer  (please mark with an "X" if appropriate)




Non-UK issuer








2. Reason for the notification (please mark the appropriate box or boxes with an "X")




An acquisition or disposal of voting rights


X




An acquisition or disposal of financial instruments








An event changing the breakdown of voting rights








Other (please specify):








3. Details of person subject to the notification obligation




Name


Richard Sharp




City and country of registered office (if applicable)








4. Full name of shareholder(s) (if different from 3.)




Name


Blind Trust (Richard Sharp)




City and country of registered office (if applicable)








5. Date on which the threshold was crossed or reachedvi:


04/06/2020




6. Date on which issuer notified (DD/MM/YYYY):


05/06/2020




7. Total positions of person(s) subject to the notification obligation








% of voting rights attached to shares (total of 8. A)


% of voting rights through financial instruments

(total of 8.B 1 + 8.B 2)


Total of both in % (8.A + 8.B)


Total number of voting rights of issuer




Resulting situation on the date on which threshold was crossed or reached


7%






7%


63,500,047




Position of previous notification (if 
applicable)


6.7%






6.7%
















 



8. Notified details of the resulting situation on the date on which the threshold was crossed or reached




A: Voting rights attached to shares




Class/type of

shares
ISIN code (if possible)


Number of voting rights


% of voting rights




Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)


Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)


Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)


Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)




GB00BYQ94H38


4,447,000






7%




















































SUBTOTAL 8. A


4,447,000


7%




 
 




B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))




Type of financial instrument


Expiration

date


Exercise/

Conversion Period


Number of voting rights that may be acquired if the instrument is 
exercised/converted.


% of voting rights














































































SUBTOTAL 8. B 1












 
 




B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))




Type of financial instrument


Expiration

date


Exercise/

Conversion Period


Physical or cash 
settlement


Number of voting rights 


% of voting rights






























































































SUBTOTAL 8.B.2












 
 
 















 



9. Information in relation to the person subject to the notification obligation (please mark the 
applicable box with an "X")




Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer


X




Full chain of controlled undertakings through which the voting rights and/or the

financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary)








Name


% of voting rights if it equals or is higher than the notifiable threshold


% of voting rights through financial instruments if it equals or is higher than the notifiable threshold


Total of both if it equals or is higher than the notifiable threshold




































































































10. In case of proxy voting, please identify:




Name of the proxy holder








The number and % of voting rights held








The date until which the voting rights will be held














11. Additional information




The Blind Trust (Richard Sharp), under the direction of the trustee, purchased 166,251 additional shares on 04/06/2020
 










 



Place of completion


London, United Kingdom
 




Date of completion


04-Jun-2020
 



 
 
For further information:
 
Oncimmune Holdings plc
Ron Kirschner, General Counsel and Company Secretary
contact@oncimmune.com   


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
HOLEAFKXELPEEAA